文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

重型COVID-19患者的感染事件:一项基础免疫缺陷高患病率队列研究的结果

Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect.
PubMed 文献 · Ann Intensive Care · 2021-05-25
一句话结论重型COVID-19中10个ICU日感染累积发生率为27%,地塞米松与感染增加相关但对死亡率无影响。

该回顾性单中心研究纳入100例因重型COVID-19入住ICU的连续患者,其中34例有基础恶性肿瘤或器官移植。感染事件10个ICU日累积发生率为27%[18-35],社区获得性感染患病率7%[2.8-13.9],医院获得性感染发病密度为每1000 ICU日125[91-200]次事件。机械通气与医院获得性感染独立相关,患者病情严重程度和基础恶性肿瘤与死亡率相关。地塞米松与感染增加相关(10天累积发生率36%[20-53] vs 12%[4-20],p=0.01),倾向性评分匹配后仍与医院获得性感染相关(10天35%[18-52] vs 13%[1-25],p=0.03),但在需要机械通气的患者亚组中除外,且对死亡率无影响。

要点

  • 10个ICU日感染累积发生率为27%[18-35],医院获得性感染发病密度为每1000 ICU日125[91-200]次事件。
  • 地塞米松与感染增加相关:10天累积发生率36%[20-53] vs 12%[4-20],p=0.01;匹配后35%[18-52] vs 13%[1-25],p=0.03。
  • 地塞米松与医院获得性感染的关联在需要机械通气的患者亚组中除外,且对死亡率无影响。
  • 机械通气是医院获得性感染的独立危险因素,患者病情严重程度和基础恶性肿瘤与死亡率相关。
  • 社区获得性感染患病率为7%[2.8-13.9];100例中34例有基础恶性肿瘤或器官移植。

适用人群与场景

  • 因重型COVID-19入住ICU的连续患者,共100例,其中34例有基础恶性肿瘤或器官移植。

研究设计与关键结果

  • 回顾性单中心研究,纳入100例因重型COVID-19入住ICU的连续患者,其中34例有基础恶性肿瘤或器官移植。
  • 首次感染事件为细菌性者35例,真菌性者1例。
  • 感染事件10个ICU日累积发生率为27%[18-35]。
  • 社区获得性感染患病率为7%[2.8-13.9]。
  • 医院获得性感染发病密度为每1000 ICU日125[91-200]次事件。
  • 与医院获得性感染独立相关的危险因素包括机械通气。
  • 患者病情严重程度和基础恶性肿瘤与死亡率相关。
  • 地塞米松与感染增加相关:10天累积发生率36%[20-53] vs 12%[4-20],p=0.01;倾向性评分匹配后,地塞米松与医院获得性感染相关:10天35%[18-52] vs 13%[1-25],p=0.03,但在需要机械通气的患者亚组中除外,且对死亡率无影响。

证据类型、等级与局限

  • 证据类型:回顾性单中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在基础免疫缺陷高患病率的重型COVID-19患者中,应注意感染风险高;机械通气和使用类固醇与感染率独立相关(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Empirical antibiotic has been considered in severe COVID-19 although little data are available regarding concomitant infections. This study aims to assess the frequency of infections, community and hospital-acquired infections, and risk factors for infections and mortality during severe COVID-19.

METHODS: Retrospective single-center study including consecutive patients admitted to the intensive care unit (ICU) for severe COVID-19. Competing-risk analyses were used to assess cumulative risk of infections. Time-dependent Cox and fine and gray models were used to assess risk factors for infections and mortality. Propensity score matching was performed to estimate the effect of dexamethasone.

RESULTS: We included 100 patients including 34 patients with underlying malignancies or organ transplantation. First infectious event was bacterial for 35 patients, and fungal for one. Cumulative incidence of infectious events was 27% [18-35] at 10 ICU-days. Prevalence of community-acquired infections was 7% [2.8-13.9]. Incidence density of hospital-acquired infections was 125 [91-200] events per 1000 ICU-days. Risk factors independently associated with hospital-acquired infections included MV. Patient's severity and underlying malignancy were associated with mortality. Dexamethasone was associated with increased infections (36% [20-53] vs. 12% [4-20] cumulative incidence at day-10; p = 0.01). After matching, dexamethasone was associated with hospital-acquired infections (35% [18-52] vs. 13% [1-25] at 10 days, respectively, p = 0.03), except in the subset of patients requiring MV, and had no influence on mortality.

CONCLUSIONS: In this population of COVID-19 patients with high prevalence of underlying immune defect, a high risk of infections was noted. MV and use of steroids were independently associated with infection rate.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Saade A, Moratelli G, Dumas G, et al. Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect. Ann Intensive Care. 2021. PMID: 34036411. doi:10.1186/s13613-021-00873-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。